Why Big Pharma is Scared of Cannabinoids – and How Medical Marijuana, Inc. is Bridging the Gap

[vc_row][vc_column][vc_column_text]As cannabis continues to expand into a multi-billion dollar international market, other sectors of the economy are beginning to feel the effects of this new industry’s growth – none more so than pharmaceuticals. This raises an important question: can marijuana and the pharmaceutical industry co-exist?

The Big Pharma Question

Big Pharma is currently losing potential profit in states that have already legalized medical marijuana. Research from the University of Georgia shows that prescription medication use is down in states with established medical marijuana programs. The average doctor in these states prescribed 265 fewer doses of antidepressants each year of the study, 486 fewer doses of seizure medication, 541 fewer anti-nausea doses, and 562 fewer doses of anti-anxiety medication. However, it was pain medication that was hardest hit, seeing an average of 1,826 fewer doses in medical marijuana states.

The researchers in the study wanted to determine just how much revenue the pharmaceutical industry has lost in medical marijuana states. In 2013, the 17 states with medical marijuana laws saved an estimated $165 million on prescription pills. Extrapolating from their findings, the team concluded that, if medical cannabis was legalized at the federal level, over $500 million would vanish from the pharmaceutical industry’s annual revenue reports.

Big Pharma has not taken this challenge to their bottom line lightly. While many pharmaceutical companies have openly lobbied against cannabis legalization, others have gone further and donated large sums to fight legalization. Insys Therapeutics, Inc., the makers of fentanyl, donated $500,000 to Arizonans for Responsible Drug Policy, an anti-cannabis group, to successfully oppose legalization in Arizona in 2016. Fentanyl, touted to be 50 times more potent than morphine, is best known for contributing to Prince’s overdose death. With the potential loss of revenue from marijuana, companies like Insys have a vested interest in preventing marijuana from becoming legal. [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_single_image image=”17843″ img_size=”1200×250″ onclick=”custom_link” link=”https://www.medicalmarijuanainc.com/medical-marijuana-can-curb-opioid-use-study-indicates/”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]However, it is possible to create new prescription drugs for these conditions using cannabinoids without interfering with cannabis’s path to legalization. Two of Medical Marijuana, Inc.’s investment companies are currently developing novel treatments using hemp-based cannabinoids like CBD, while Medical Marijuana, Inc. itself supported California’s successful legalization effort with a donation, proving the relationship between marijuana and pharmaceuticals doesn’t need to be contentious.

Few companies though have the resources necessary to develop cannabis-based treatments by working directly with the DEA, which requires costly fees and intensive oversight of the testing and development process.

AXIM® Biotechnologies

AXIM® Biotechnologies, a Medical Marijuana, Inc. investment company, just recently received the funding needed to pursue multiple clinical trials on cannabinoid derived drugs.

The company’s cannabinoid-infused chewing gum MedChew® RX is being prepared for trials for the pain and spasticity associated with multiple sclerosis. The study is scheduled to take 12 months and should be followed by FDA/EMA registration as a novel treatment for MS.

AXIM® is also running clinical trials on its CanChew® Plus cannabinoid chewing gum to determine the formulation’s potential as a treatment for Irritable Bowel Syndrome (IBS). The study will test two different potencies of CanChew® gum to choose the ideal dosing for the next phase of trials.

Finally, AXIM® Biotechnologies is pursuing clinical studies on its proprietary topical cannabinoid application, AX-1602. AXIM® plans to test AX-1602 for the treatment of psoriasis and eczema. The company’s patent pending topical is made using cannabigerol or CBG, known as the “stem cell cannabinoid” for its ability to become any other cannabinoid.

Kannalife™ Sciences

Another of Medical Marijuana, Inc.’s investment companies, Kannalife™ Sciences is also working to develop novel new treatments derived from cannabinoids. Using their licenses on the government’s patent 6,630,507, Cannabinoids as antioxidants and neuroprotectants, Kannalife™ Sciences is developing new cannabinoid-based medications for a pair of degenerative brain conditions, hepatic encephalopathy and chronic traumatic encephalopathy.

Hepatic encephalopathy (HE) results when the liver cannot function properly, allowing toxins to reach the brain and damaging functionality. HE typically occurs in those with chronic liver disease. Chronic traumatic encephalopathy is the result of repeated blows to the head. Linked to concussions, CTE is estimated to affect over 90% of NFL players, but may be found in anyone with head injuries.

Although Kannalife™ Sciences is focusing on these two conditions in their research now, the company’s work can open up treatments for a number of other neurodegenerative diseases, like Alzheimer’s disease and Parkinson’s disease. [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_single_image image=”17365″ img_size=”1200×250″ onclick=”custom_link” link=”https://www.medicalmarijuanainc.com/overview-of-medical-marijuana-research/”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

The Future of Cannabis Medicines

Although the DEA recently rejected requests to reschedule cannabis out of Schedule I, the classification saved for the most dangerous drugs, the agency’s new policies have opened the door for increased research into the plant to examine its medicinal potential.

It will be this medical research that eventually solidifies the pathway of further cannabis-based drugs to FDA approval. It is unlikely that the FDA will ever endorse smokeable or edible whole plant marijuana as medicine, and instead, pharmaceutical companies will have to follow the traditional path to new drug designation, including intense clinical research to prove safety and efficacy.

The FDA has already approved cannabis-based drugs in the past. Once approved, the drug itself is then classified separately from whole plant marijuana. For example, Marinol, a synthetic THC medication, is classified as a Schedule III drug, and is available by prescription for cancer and AIDS patients.

Looking toward a future pharmaceutical market that includes cannabinoid-based medications, Medical Marijuana, Inc. and its investment companies are actively pursuing the medical research, new drug development, and clinical trials that will be necessary to establish cannabis as an FDA approved medicine.

For more news on these and other Medical Marijuana, Inc. investments, follow our news feed. [/vc_column_text][/vc_column][/vc_row]